$INTI
Inhibitor Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000119312522219960 Filed on August 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $69.99K $64.65K $93.50K
YoY Change 5.65% 4.8% -42.94%
% of Gross Profit
Research & Development $0.00 $6.150K $0.00
YoY Change 547.37% -100.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $69.99K $70.80K $93.50K
YoY Change 5.64% 13.04% -44.26%
Operating Profit -$69.99K -$70.80K -$93.50K
YoY Change 5.64% 13.04% -44.26%
Interest Expense -$7.710K -$6.760K -$5.410K
YoY Change 60.63% 90.42% 220.12%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$77.69K -$77.57K -$98.91K
YoY Change 9.35% 17.21% -22.63%
Income Tax
% Of Pretax Income
Net Earnings -$77.69K -$77.57K -$98.91K
YoY Change 9.35% 17.2% -22.63%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$262.50
COMMON SHARES
Basic Shares Outstanding 376.9M 376.9M 376.9M shares
Diluted Shares Outstanding 376.9M 376.9M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.06K $24.95K $36.44K
YoY Change -0.43% -73.38% -56.72%
Cash & Equivalents $53.06K $24.95K $36.44K
Short-Term Investments
Other Short-Term Assets $10.06K $13.57K $24.71K
YoY Change -72.66% -58.93% -32.84%
Inventory
Prepaid Expenses $10.06K $13.57K
Receivables
Other Receivables
Total Short-Term Assets $63.12K $38.52K $61.14K
YoY Change -29.93% -69.61% -49.46%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL ASSETS
Total Short-Term Assets $63.12K $38.52K $61.14K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $63.12K $38.52K $61.14K
YoY Change -31.78% -71.79% -55.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $326.5K $311.9K $321.7K
YoY Change 7.1% 3.94% -0.09%
Accrued Expenses $34.85K $27.14K $20.38K
YoY Change 243.01% 406.34%
Deferred Revenue
YoY Change
Short-Term Debt $411.0K $331.0K $281.0K
YoY Change 113.51% 145.64% 440.38%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.088M $935.0K $830.2K
YoY Change 84.08% 68.51% 91.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change -1.27% -3.11% -3.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.088M $935.0K $830.2K
Total Long-Term Liabilities $3.000M $3.000M $3.000M
Total Liabilities $4.088M $3.935M $3.830M
YoY Change 12.63% 7.78% 8.3%
SHAREHOLDERS EQUITY
Retained Earnings -$58.07M -$57.95M
YoY Change
Common Stock $50.09M $50.09M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.025M -$3.897M -$3.769M
YoY Change
Total Liabilities & Shareholders Equity $63.12K $38.52K $61.14K
YoY Change -31.78% -71.79% -55.72%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$77.69K -$77.57K -$98.91K
YoY Change 9.35% 17.2% -22.63%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$51.89K -$61.49K -$44.19K
YoY Change 28.35% -6.08% -51.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 80.00K 50.00K 50.00K
YoY Change -33.33% -50.5%
NET CHANGE
Cash From Operating Activities -51.89K -61.49K -44.19K
Cash From Investing Activities
Cash From Financing Activities 80.00K 50.00K 50.00K
Net Change In Cash 28.11K -11.49K 5.810K
YoY Change -169.53% -220.57% -36.36%
FREE CASH FLOW
Cash From Operating Activities -$51.89K -$61.49K -$44.19K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
26391
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-105681
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157343
dei Document Type
DocumentType
10-Q
CY2021Q4 us-gaap Liabilities
Liabilities
3679630
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Document Transition Report
DocumentTransitionReport
false
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
dei Entity File Number
EntityFileNumber
001-13467
dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0793665
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Address Address Line1
EntityAddressAddressLine1
449 South 12th Street
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
100000
dei Entity Address Address Line2
EntityAddressAddressLine2
Unit 1705
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
dei Entity Address City Or Town
EntityAddressCityOrTown
Tampa
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33602
dei City Area Code
CityAreaCode
888
dei Local Phone Number
LocalPhoneNumber
841-6811
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
176000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
376858323
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24945
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
376858323
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
376858323
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
376858323
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
376858323
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30626
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
13572
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
28158
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
935019
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
679630
CY2022Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
38517
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2022Q2 us-gaap Liabilities
Liabilities
3935019
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58784
CY2021Q4 us-gaap Assets Current
AssetsCurrent
58784
CY2022Q2 us-gaap Assets
Assets
38517
CY2021Q4 us-gaap Assets
Assets
58784
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
311878
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
279842
CY2022Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
200002
CY2021Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100823
CY2022Q2 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
331000
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
231000
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
27139
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
14965
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
65000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
53000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
37686
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
37686
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50051711
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50051711
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57946765
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57671109
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3896502
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3620846
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38517
CY2021Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49863
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
99178
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
99178
CY2022Q2 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-127430
CY2022Q2 us-gaap Revenues
Revenues
0
CY2021Q2 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-116045
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-275655
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-293198
CY2021Q2 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6150
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
950
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6150
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4830
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64654
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
61685
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
158154
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
225558
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
70804
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
62635
us-gaap Operating Expenses
OperatingExpenses
164304
us-gaap Operating Expenses
OperatingExpenses
230388
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-70804
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-62635
us-gaap Operating Income Loss
OperatingIncomeLoss
-164304
us-gaap Operating Income Loss
OperatingIncomeLoss
-230388
CY2022Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
6763
CY2021Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
3547
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
12173
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
5232
CY2022Q2 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
CY2021Q2 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
41600
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-77567
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-66182
us-gaap Net Income Loss
NetIncomeLoss
-176477
us-gaap Net Income Loss
NetIncomeLoss
-194020
CY2022Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49863
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376858323
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
41600
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14586
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376858323
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
375876361
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-13896
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
375876361
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376858323
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376858323
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
56210
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
375703064
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
375703064
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3620846
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-98910
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3769071
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49864
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-77567
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-3896502
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3360203
CY2021Q1 us-gaap Stock Issued During Period Value Dividend Reinvestment Plan
StockIssuedDuringPeriodValueDividendReinvestmentPlan
100822
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
37990
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-127838
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-3398544
CY2021Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-66182
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-3514589
us-gaap Profit Loss
ProfitLoss
-176477
us-gaap Profit Loss
ProfitLoss
-194020
us-gaap Share Based Compensation
ShareBasedCompensation
0
us-gaap Share Based Compensation
ShareBasedCompensation
37990
us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
100000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
176000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5681
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18657
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30626
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75059
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24945
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93716
us-gaap Stock Issued1
StockIssued1
0
us-gaap Stock Issued1
StockIssued1
100822
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
99178
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
99178
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
inti Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24945
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Estimates </div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div>
CY2022Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
231000
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
281000

Files In Submission

Name View Source Status
0001193125-22-219960-index-headers.html Edgar Link pending
0001193125-22-219960-index.html Edgar Link pending
0001193125-22-219960.txt Edgar Link pending
0001193125-22-219960-xbrl.zip Edgar Link pending
d312904d10q.htm Edgar Link pending
d312904dex311.htm Edgar Link pending
d312904dex312.htm Edgar Link pending
d312904dex321.htm Edgar Link pending
d312904dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
inti-20220630.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
inti-20220630_def.xml Edgar Link unprocessable
inti-20220630_lab.xml Edgar Link unprocessable
inti-20220630_pre.xml Edgar Link unprocessable
d312904d10q_htm.xml Edgar Link completed
inti-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable